(MedPage Today) — In the decade since palbociclib (Ibrance) was approved by the FDA, results from several clinical trials have provided a strong evidence base for manufacturing cyclin-dependent kinase (CDK) 4/6 inhibitors, in combination with endocrine therapy…
